Maintaining and expanding harm reduction services in the Australian Capital Territory (ACT) could generate over $250 million in health and societal benefits from 2026 to 2030. This projection comes from a new analysis conducted by the Burnet Institute, highlighting a benefit-cost ratio of approximately 10:1. In practical terms, this means every dollar invested in these services could return more than $10 in benefits.
The study, commissioned by ACT Health and in collaboration with the Australian National University, underscores the effectiveness of common harm reduction strategies. Services such as take-home naloxone, opioid agonist treatment, and needle-syringe programs not only mitigate the negative consequences of drug use but also present significant economic advantages.
Economic Benefits of Harm Reduction Services
The analysis notably identified that expanding opioid agonist treatments—like methadone or buprenorphine utilized for treating opioid dependence—could yield one of the highest returns. The research indicates that such programs could offer over $10 in benefits for every $1 invested, primarily through reductions in overdoses, deaths, and injection-related harms.
Additionally, the study explored the cost-effectiveness of introducing new interventions, specifically drug consumption rooms. These facilities demonstrated potential for reducing overdose deaths, minimizing ambulance callouts, and lowering hospitalization costs associated with injection-related infections. Notably, a nurse- or peer-led model for drug consumption rooms showed a higher return on investment compared to doctor-led models seen in other Australian regions.
Professor Paul Dietze, who serves as the Burnet Program Director of Disease Elimination, commented on the findings, stating, “For every dollar invested, a drug consumption room could return up to nearly $3 in benefits through avoided overdose deaths, reduced ambulance callouts, and shorter hospital stays.” He emphasized that these facilities are a proven, cost-effective means of reducing preventable deaths and facilitating access to health services while alleviating pressure on emergency resources.
Adapting to Evolving Drug Markets
The modelling also considered a scenario involving the increased presence of potent synthetic opioids in the ACT drug market, a trend already observed in other parts of Australia. The analysis revealed that under these high-risk conditions, the cost-effectiveness of harm reduction interventions escalated significantly.
This comprehensive study highlights the critical importance of sustained investment in harm reduction services, providing vital evidence that can guide future policy decisions as drug-related risks continue to evolve. The full analysis, titled “A cost-benefit analysis of the implementation and scale-up of harm reduction interventions in the Australian Capital Territory,” is available in the journal Addiction.
The research was conducted as a collaboration between the Burnet Institute and the Australian National University, receiving funding support from the ACT Health Directorate. The authors acknowledge the contributions of the Victorian Operational Infrastructure Support Program, which has supported the Burnet Institute’s work.
As drug-related health challenges persist, the findings from this analysis advocate for proactive strategies that not only save lives but also yield substantial economic returns for society.
